Skip to main navigation
HomeContact Us
×
 
About Us
About Us
About Alkermes
Our CompanyMessage From the CEOLocations
Leadership
Management TeamBoard of Directors
Collaborations
Strategic Partners
Products
Products
Products
Products Overview
United States
ARISTADA ® VIVITROL ®Proprietary Products and TechnologiesWholesaler and Purchasing Information
European Union
EU Products Using Alkermes Technologies
Research & Development
Research & Development
Research & Development
R&D OverviewOur R&D ApproachPipelineTechnology PlatformsManufacturing
Other Information
Clinical TrialsExpanded Access
Responsibility
Responsibility
Responsibility
Corporate Responsibility Corporate Giving and Funding Alkermes Inspiration Grants® COVID-19 Relief Fund Medical Education Grants Alkermes Pathways Research Awards® Investigator Sponsored Studies Public Policy
Investors
Investors
Investors
Corporate Overview Press Releases Investor Events Stock Information SEC Filings Annual Reports
Financials
Snapshot Trading Statistics
Other Information
Email Alerts
News & Events
News & Events
News & Events
Press ReleasesMedia Kit
Careers
Careers
Careers
Working TogetherOur Core ValuesTotal RewardsMeet Our EmployeesRecruiting AgenciesEqual Opportunity EmployerJobs Overview
Job Opportunities
Field Sales RolesAll Available Roles

Investors

Home Investors Press Releases

Investors

Corporate Overview Press Releases Investor Events Stock Information SEC Filings Annual Reports

Financials

Snapshot Trading Statistics

Other Information

Email Alerts

Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
02/18/21 Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference
PDF Version
02/11/21 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
PDF Version
02/04/21 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
PDF Version
01/14/21 NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
PDF Version
01/06/21 Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
PDF Version
01/06/21 Alkermes Announces Updates to Executive Leadership Team
PDF Version
Contact UsTerms of UsePrivacy PolicySitemap
Follow Us:
©2021 Alkermes. All Rights Reserved